Biology Reference
In-Depth Information
[51] Min CK, Kim SY, Lee MJ, Eom KS, Kim YJ, Kim HJ, et al. Vascular endothelial growth
factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and
nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant
2006;38:149-56.
[52] Nachbaur D, Schumacher P, Auberger J, Clausen J, Kircher B. Vascular endothelial
growth factor and activin-a serum levels following allogeneic hematopoietic stem cell
transplantation. Biol Blood Marrow Transplant 2007;13:942-7.
[53] Jiang S, Walker L, Afentoulis M, Anderson DA, Jauron-Mills L, Corless CL, et al. Trans-
planted human bone marrow contributes to vascular endothelium. Proc Natl Acad Sci
USA 2004;101:16891-6.
[54] Murata H, Janin A, Leboeuf C, Soulier J, Gluckman E, Meignin V, et al. Donor-derived
cells and human graft-versus-host disease of the skin. Blood 2007;109:2663-5.
[55] Willemze AJ, Bakker AC, von dem Borne PA, Bajema IM, Vossen JM. The effect of
graft-versus-host disease on skin endothelial and epithelial cell chimerism in stem-cell
transplant recipients. Transplantation 2009;87:1096-101.
[56] Mueller RJ, Stussi G, Puga Yung G, Nikolic M, Soldini D, Halter J, et al. Persistence of
recipient-type endothelium after allogeneic hematopoietic stem cell transplantation.
Haematologica 2011;96:119-27.
[57] Hernandez GL, Volpert OV, Iniguez MA, Lorenzo E, Martinez-Martinez S, Grau R, et al.
Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by
cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp
Med 2001;193:607-20.
[58] Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for
angiogenesis. J Exp Med 1971;133:275-88.
[59] Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with
acute myeloid leukemia. Blood 2000;95:309-13.
[60] Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, et al. Prognostic value of
enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia.
Blood 2002;100:3344-51.
[61] Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, et al. Bone marrow neovas-
cularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion
parallel progression of human multiple myeloma. Blood 1999;93:3064-73.
[62] Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in
acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.
[63] Schmidt T, Carmeliet P. Angiogenesis: a target in solid tumors, also in leukemia?. Hema-
tology Am Soc Hematol Educ Program 2011;2011:1-8.
[64] Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular
endothelial growth factor, a possible paracrine growth factor in human acute myeloid
leukemia. Blood 1997;89:1870-5.
[65] Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al. Autocrine stimulation
of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest
2000;106:511-21.
[66] Wakabayashi M, Miwa H, Shikami M, Hiramatsu A, Ikai T, Tajima E, et al. Autocrine
pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-
inositol 3 kinase. Hematol J 2004;5:353-60.
[67] Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, et al. Analysis of concerted
expression of angiogenic growth factors in acute myeloid leukemia: expression of angio-
poietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol
2005;23:1109-17.
[68] Lal D, Park JA, Demock K, Marinaro J, Perez AM, Lin MH, et al. Aflibercept exerts antivas-
cular effects and enhances levels of anthracycline chemotherapy in vivo in human acute
myeloid leukemia models. Mol Cancer Ther 2010;9:2737-51.
[69] Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, et al. Bevacizumab potentiates
chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor
endothelial cells. Haematologica 2011;96:927-31.
[70] Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, et al. Inhibition of human leu-
kemia in an animal model with human antibodies directed against vascular endothelial
growth factor receptor 2: correlation between antibody affinity and biological activity.
Leukemia 2003;17:604-11.
[71] Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, et al. Inhibition of both paracrine
and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-
term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA
2001;98:10857-62.
[72] Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, et al.
Leukemia regression by vascular disruption and antiangiogenic therapy. Blood
2010;116:1539-47.
491
Search WWH ::
Custom Search